AVCT — Avacta Share News
0.000.00%
Last trade - 00:00- £298.72m
- £298.32m
- £0.11m
Highlights pre|CISION® Platform Data
To Present on AVA6000 and AVA6103 at ESMO 2026
Notice of Interim Results Investor Meeting
AIM - AIM Notice - 09/10/2026
Results of Placing and Subscription
Proposed Fundraise to raise approximately £12.5m
Brief: Avacta Therapeutics Announces Intention To Use AIM Capital Access Window For Equity Fundraise
Capital Access Window
Interim Results for Six Months to June 30, 2026
pre|CISION® Platform Wins R&D Achievement Award
Further Demonstration of Potential of AVA6103
Brief: Avacta says AVA6103 drug candidate achieves proof of mechanism in Phase 1 trial
Clinical Proof of Mechanism for preCISION Platform
Mats Blom to Board as Chair of Audit Committee
Accelerated Payment Convertible Bond Installment
Share Option Awards to Management Team at Avacta
Accelerated Amortized Payment of Bond Installment
Avacta Appoints Patrick Vink Deputy Chairman
Brief: Avacta Group Reports Platform-Validating Data With Faridoxorubicin